Get started
ELICERA THERAPEUTICS ABELICERA THERAPEUTICS ABELICERA THERAPEUTICS AB

ELICERA THERAPEUTICS AB

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

ELIC fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Elicera Therapeutics AB operates as a clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. Its drug candidates are in the field of oncolytic viruses and in the field of cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields. Its product pipeline includes ELC-100, ELC-201, ELC-301, and ELC-401. The company was founded by Jamal El-Mosleh, Di Yu, and Magnus Essand in 2014 and is headquartered in Gothenburg, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ELIC does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company